All News

Found 42,013 articles

• Neutron Therapeutics Announces Successful Generation of a Neutron Beam for BNCT at Shonan Kamakura General Hospital in Japan

  1/12/2023

  Neutron Therapeutics (NT) today announced the successful production of a proton beam at an industry-leading 37mA of proton current on target, and the generation of the first neutron beam at its nuBeam® system at Shonan Kamakura General Hospital (SKGH) in Kanagawa Prefecture, Japan.

• HVR CARDIO CLOSES ON $11 Million SERIES B FINANCING WITH FINLAND'S INNOVESTOR LIFE SCIENCE FUND AND TESI

  1/12/2023

  HVR Cardio, a clinical stage medical technology company developing Structural Heart cardiovascular products for transcatheter mitral valve repair, announced today that it has closed on its 10.7 million Euro ($11.1M US) Series B Round of financing.

• Ariadne Labs Announces 2022-2023 Spark Grant Recipients

  1/11/2023

  Ariadne Labs announced five recipients of the Ariadne Labs Spark Grant innovation awards for the 2022-2023 year.

• The American Diabetes Association Welcomes 2023 Principal Officers and New Members to the National Board of Directors

  1/11/2023

  The American Diabetes Association® welcomes the 2023 Principal Officers and Board of Directors.

• XtalPi Names New COO for U.S. Operations, Bringing Its Autonomous Labs to Boston in Continued Global Expansion

  1/11/2023

  XtalPi, Inc., a pioneering pharmaceutical technology company powered by artificial intelligence and automation, announced that Dr. Sarah Trice has joined the company as chief operating officer of U.S. operations.

• Inflammation Levels Tied to Severity of Blood Cancer

  1/11/2023

  Severe inflammation weakens the body's ability to kill cancerous blood cells in people with acute myeloid leukemia (AML), a new study shows.

• Ginkgo Bioworks Provides Preliminary Unaudited 2022 Revenue Highlights and Business Review

  1/11/2023

  Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today preliminary performance updates for the year ended December 31, 2022.

• CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference

  1/11/2023

  CRISPR Therapeutics today announced that members of its senior management team are scheduled to participate in B. Riley Securities’ 3rd Annual Oncology Conference on Wednesday, January 18, 2023, at 10:30 a.m. ET.

• Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium

  1/11/2023

  Bicycle Therapeutics plc today announced that monotherapy dose escalation results of the ongoing Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4, will be presented at the 2023 American Society for Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, being held February 16-18, 2023 in San Francisco, California.

• 

  JPM Day 2: Highlights

  1/10/2023

  Stay on top of what's happening at JPM. BioSpace is covering all the key announcements all week.

• Penumbra Launches Latest Innovation in Mechanical Thrombectomy: Lightning Flash™

  1/10/2023

  Penumbra, Inc., a global healthcare company focused on innovative therapies, announced the U.S. Food and Drug Administration clearance and launch of Lightning Flash™, the most advanced and powerful mechanical thrombectomy system on the market.

• RoslinCT and Lykan Bioscience Announce the Appointment of Dr. Michael Mendicino to its Scientific Advisory Board

  1/10/2023

  RoslinCT and Lykan Bioscience, a leader in Contract Development and Manufacturing for cell therapies, announced the appointment of Michael Mendicino, Ph.D. to its Scientific Advisory Board.

• Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company

  1/10/2023

  Kymera Therapeutics, Inc. today announced its research, development and corporate goals for 2023.

• Instylla Announces Enrollment of Initial Patient in the Prospective Multicenter HALT Study

  1/10/2023

  Instylla, Inc. today announced the enrollment of the first patient in the HALT Study1 for the treatment of peripheral arterial bleeds.

• Hilltop BioSciences Introduces New Regenerative Therapy Formulations for Companion Animals at VMX (Booth s5027)

  1/10/2023

  Hilltop BioSciences, a veterinary biotech company pioneering the development of innovative regenerative therapies, will be introducing several new formulations at VMX in Orlando where they will be showcased in the Startup Circle (Booth s5027).

• Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics

  1/10/2023

  Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics.

• Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)

  1/10/2023

  Pieris Pharmaceuticals, Inc. today announced that the Company has achieved a $5 million milestone from Seagen.

• BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development

  1/10/2023

  BioNTech SE (Nasdaq: BNTX, “BioNTech”) and InstaDeep Ltd. (“InstaDeep”) today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence (“AI”) and machine learning (“ML”).

• Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia

  1/10/2023

  Hemab Therapeutics, a clinical-stage biotechnology company developing next-generation therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the first patient has been dosed in a Phase 1/2 study evaluating HMB-001 for the treatment of the severe bleeding disorder Glanzmann Thrombasthenia (Glanzmann).

• Cerveau Technologies Inc. and Prothena Sign Agreement to Provide Novel Tau Imaging Biomarker for Research and Development of Investigational Therapeutics for Neurodegenerative Diseases

  1/10/2023

  Cerveau Technologies, Inc. today announced a research collaboration agreement with Othair Prothena Limited, a subsidiary of Prothena Corporation plc (Prothena), which will enable Prothena to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.